WO2023186069A1 - Composé hétérocyclique chimérique bifonctionnel de la kinase 4 associée au récepteur de l'interleukine-1, son procédé de préparation, composition pharmaceutique de celui-ci et utilisation associée - Google Patents
Composé hétérocyclique chimérique bifonctionnel de la kinase 4 associée au récepteur de l'interleukine-1, son procédé de préparation, composition pharmaceutique de celui-ci et utilisation associée Download PDFInfo
- Publication number
- WO2023186069A1 WO2023186069A1 PCT/CN2023/085387 CN2023085387W WO2023186069A1 WO 2023186069 A1 WO2023186069 A1 WO 2023186069A1 CN 2023085387 W CN2023085387 W CN 2023085387W WO 2023186069 A1 WO2023186069 A1 WO 2023186069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- hydrogen
- pharmaceutically acceptable
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 102
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 title abstract description 47
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 title abstract description 47
- 230000001588 bifunctional effect Effects 0.000 title abstract description 13
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 230000001404 mediated effect Effects 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 255
- -1 cyano, hydroxyl Chemical group 0.000 claims description 229
- 125000000623 heterocyclic group Chemical group 0.000 claims description 171
- 229910052739 hydrogen Inorganic materials 0.000 claims description 139
- 239000001257 hydrogen Substances 0.000 claims description 131
- 125000003118 aryl group Chemical group 0.000 claims description 109
- 125000001072 heteroaryl group Chemical group 0.000 claims description 105
- 150000002431 hydrogen Chemical class 0.000 claims description 95
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 79
- 150000003839 salts Chemical class 0.000 claims description 79
- 239000012453 solvate Substances 0.000 claims description 78
- 229940002612 prodrug Drugs 0.000 claims description 77
- 239000000651 prodrug Substances 0.000 claims description 77
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 76
- 230000003287 optical effect Effects 0.000 claims description 73
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 63
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 54
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 49
- 125000002947 alkylene group Chemical group 0.000 claims description 42
- 125000004419 alkynylene group Chemical group 0.000 claims description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 41
- 229910052801 chlorine Inorganic materials 0.000 claims description 39
- 229910052731 fluorine Inorganic materials 0.000 claims description 38
- 125000004043 oxo group Chemical group O=* 0.000 claims description 37
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 34
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 239000002994 raw material Substances 0.000 claims description 29
- 125000004450 alkenylene group Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 25
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 24
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 229920006395 saturated elastomer Polymers 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 229910052794 bromium Inorganic materials 0.000 claims description 21
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims description 16
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 14
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 230000000155 isotopic effect Effects 0.000 claims description 12
- 125000001010 sulfinic acid amide group Chemical group 0.000 claims description 12
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 11
- 229910052721 tungsten Inorganic materials 0.000 claims description 11
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 102000003960 Ligases Human genes 0.000 claims description 8
- 108090000364 Ligases Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 4
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 208000016361 genetic disease Diseases 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 238000006268 reductive amination reaction Methods 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 claims description 3
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims 7
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 238000006482 condensation reaction Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 9
- 238000006731 degradation reaction Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000034512 ubiquitination Effects 0.000 abstract description 2
- 238000010798 ubiquitination Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 421
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 189
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 182
- 238000003786 synthesis reaction Methods 0.000 description 180
- 239000000243 solution Substances 0.000 description 176
- 230000015572 biosynthetic process Effects 0.000 description 170
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 159
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 155
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 119
- 230000002829 reductive effect Effects 0.000 description 101
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 89
- 239000012141 concentrate Substances 0.000 description 88
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 85
- 239000012074 organic phase Substances 0.000 description 79
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 77
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 75
- 239000000543 intermediate Substances 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 72
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 61
- 235000019439 ethyl acetate Nutrition 0.000 description 61
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 125000004432 carbon atom Chemical group C* 0.000 description 41
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 229960000583 acetic acid Drugs 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 238000004809 thin layer chromatography Methods 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 125000006413 ring segment Chemical group 0.000 description 28
- 238000003756 stirring Methods 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 27
- 239000012065 filter cake Substances 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- 239000012043 crude product Substances 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 20
- 238000010791 quenching Methods 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000005909 Kieselgur Substances 0.000 description 11
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 9
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000019260 propionic acid Nutrition 0.000 description 9
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 8
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 8
- 238000001308 synthesis method Methods 0.000 description 8
- DRAQIXNADYAISI-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound N#CC1=CN=C2NC=CC2=C1 DRAQIXNADYAISI-UHFFFAOYSA-N 0.000 description 7
- AGHXYRKTAZEQQW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindole-1,3-dione Chemical compound O=C1C=2C=C(F)C(F)=CC=2C(=O)N1C1CCC(=O)NC1=O AGHXYRKTAZEQQW-UHFFFAOYSA-N 0.000 description 7
- SYSXMSZWNCAJBG-UHFFFAOYSA-N 6-chloro-4-(methylamino)pyridine-3-carbohydrazide Chemical compound CNc1cc(Cl)ncc1C(=O)NN SYSXMSZWNCAJBG-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 6
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 6
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- MPQLCQKBYRSPNA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)N1C1CCC(=O)NC1=O MPQLCQKBYRSPNA-UHFFFAOYSA-N 0.000 description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 5
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- NSILYQWHARROMG-QMMMGPOBSA-N tert-butyl (3s)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@H](CO)C1 NSILYQWHARROMG-QMMMGPOBSA-N 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 4
- GELZPNPRRUOMMG-UHFFFAOYSA-N 2-formyl-4-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoic acid Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)C1=CC=C(C(O)=O)C(C=O)=C1 GELZPNPRRUOMMG-UHFFFAOYSA-N 0.000 description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 4
- RTGYXYYWJABYDE-UHFFFAOYSA-N 4-bromo-3-methyl-1h-benzimidazol-2-one Chemical compound C1=CC=C2NC(=O)N(C)C2=C1Br RTGYXYYWJABYDE-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- KXMRDHPZQHAXML-KYZUINATSA-N CC(C)(C)OC(=O)N[C@H]1CC[C@H](C(O)=O)CC1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](C(O)=O)CC1 KXMRDHPZQHAXML-KYZUINATSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 3
- PPMQUPLZZWUHNG-UHFFFAOYSA-N 1-(6-piperazin-1-ylpyridin-3-yl)-1,3-diazinane-2,4-dione Chemical compound C1CN(C(=O)NC1=O)C2=CN=C(C=C2)N3CCNCC3 PPMQUPLZZWUHNG-UHFFFAOYSA-N 0.000 description 3
- QPVQZYDBYVUWDP-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carboxylic acid Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N4CCC(CC4)C(=O)O QPVQZYDBYVUWDP-UHFFFAOYSA-N 0.000 description 3
- GKOPRQIPIOLXBQ-UHFFFAOYSA-N 1-[6-(4-acetylpiperazin-1-yl)pyridin-3-yl]-1,3-diazinane-2,4-dione Chemical compound CC(=O)N1CCN(CC1)C2=NC=C(C=C2)N3CCC(=O)NC3=O GKOPRQIPIOLXBQ-UHFFFAOYSA-N 0.000 description 3
- GFCKACFUYUKAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-piperazin-1-ylisoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N1CCNCC1)=O)=O GFCKACFUYUKAPW-UHFFFAOYSA-N 0.000 description 3
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
- ODMQHYXPTUCRDC-UHFFFAOYSA-N 2-bromo-n-methyl-6-nitroaniline Chemical compound CNC1=C(Br)C=CC=C1[N+]([O-])=O ODMQHYXPTUCRDC-UHFFFAOYSA-N 0.000 description 3
- AFVMOADXROQJNT-UHFFFAOYSA-N 2-chloro-5-iodo-n-methylpyridin-4-amine Chemical compound CNC1=CC(Cl)=NC=C1I AFVMOADXROQJNT-UHFFFAOYSA-N 0.000 description 3
- DLCVZLIXJWBLJS-UHFFFAOYSA-N 2-chloro-n-methylpyridin-4-amine Chemical compound CNC1=CC=NC(Cl)=C1 DLCVZLIXJWBLJS-UHFFFAOYSA-N 0.000 description 3
- YXBJFDYJCHKHHZ-UHFFFAOYSA-N 3-[[6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-3-yl]amino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C1=CC=C(C=N1)NCCC(=O)O YXBJFDYJCHKHHZ-UHFFFAOYSA-N 0.000 description 3
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 3
- BVQOQXXITQULGQ-UHFFFAOYSA-N 3-bromo-2-n-methylbenzene-1,2-diamine Chemical compound CNC1=C(N)C=CC=C1Br BVQOQXXITQULGQ-UHFFFAOYSA-N 0.000 description 3
- AXLZMTUJQWSFSF-UHFFFAOYSA-N 3-hydroxy-1-[(4-methoxyphenyl)methyl]piperidine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(O)CCC1=O AXLZMTUJQWSFSF-UHFFFAOYSA-N 0.000 description 3
- NMAPACFXKRHBEG-UHFFFAOYSA-N 4-bromo-3-methyl-1-(2-trimethylsilylethoxymethyl)benzimidazol-2-one Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)C(=O)N(C)C2=C1Br NMAPACFXKRHBEG-UHFFFAOYSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XDOGLSZAOXRKPK-UHFFFAOYSA-N methyl 4,5-difluoro-2-methylbenzoate Chemical compound COC(=O)C1=CC(F)=C(F)C=C1C XDOGLSZAOXRKPK-UHFFFAOYSA-N 0.000 description 3
- MCMCCUAPYAUWBV-UHFFFAOYSA-N methyl 6-chloro-4-(methylamino)pyridine-3-carboxylate Chemical compound CNC1=CC(Cl)=NC=C1C(=O)OC MCMCCUAPYAUWBV-UHFFFAOYSA-N 0.000 description 3
- 229940050176 methyl chloride Drugs 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- MVGGHUWSNJKACX-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-5-oxooxolane-2-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1OC(=O)CC1 MVGGHUWSNJKACX-UHFFFAOYSA-N 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 3
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108010026668 snake venom protein C activator Proteins 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- NSILYQWHARROMG-MRVPVSSYSA-N tert-butyl (3r)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@@H](CO)C1 NSILYQWHARROMG-MRVPVSSYSA-N 0.000 description 3
- ZKXCMDBKBXJMBK-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(CO)C1 ZKXCMDBKBXJMBK-UHFFFAOYSA-N 0.000 description 3
- RMHRRMBFHGEDSR-UHFFFAOYSA-N tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=N1 RMHRRMBFHGEDSR-UHFFFAOYSA-N 0.000 description 3
- BDDNPHOMXFFAAI-UHFFFAOYSA-N tert-butyl 4-prop-2-ynoxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OCC#C)CC1 BDDNPHOMXFFAAI-UHFFFAOYSA-N 0.000 description 3
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 2
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 2
- MGMBTDXCNDOKOP-UHFFFAOYSA-N 1-bromo-2,3-difluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C(Br)=C1 MGMBTDXCNDOKOP-UHFFFAOYSA-N 0.000 description 2
- HAROKQXDLYCEQV-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC2=C1C=CN2 HAROKQXDLYCEQV-UHFFFAOYSA-N 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- JRWAEKVMPVNELT-UHFFFAOYSA-N 2-[[(2,6-dioxopiperidin-3-yl)amino]methyl]-4-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoic acid Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)c1ccc(C(O)=O)c(CNC2CCC(=O)NC2=O)c1 JRWAEKVMPVNELT-UHFFFAOYSA-N 0.000 description 2
- LWSFJQDGVKEJMP-UHFFFAOYSA-N 3-chloro-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(Cl)=CNC2=N1 LWSFJQDGVKEJMP-UHFFFAOYSA-N 0.000 description 2
- ZQJNPHCQABYENK-UHFFFAOYSA-N 4-methoxycarbonylcyclohexane-1-carboxylic acid Chemical compound COC(=O)C1CCC(C(O)=O)CC1 ZQJNPHCQABYENK-UHFFFAOYSA-N 0.000 description 2
- XIJNYZNGFVAMRZ-UHFFFAOYSA-N 4h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1C(C#N)=CN=C2N=CC=C21 XIJNYZNGFVAMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
- AWNRAAVXFSTMQS-UHFFFAOYSA-N 6-bromo-1h-benzo[cd]indol-2-one Chemical compound N1C(=O)C2=CC=CC3=C2C1=CC=C3Br AWNRAAVXFSTMQS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RMODNRAIBFTCEC-UHFFFAOYSA-N BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(NC(CC1)=O)=O Chemical compound BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(NC(CC1)=O)=O RMODNRAIBFTCEC-UHFFFAOYSA-N 0.000 description 2
- GNOQFTGXINPIEC-UHFFFAOYSA-N BrC1=NN=C(S1)N1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound BrC1=NN=C(S1)N1CCC(CC1)NC(OC(C)(C)C)=O GNOQFTGXINPIEC-UHFFFAOYSA-N 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- MZNGRBNGYVGABU-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC1)c1ccc(C(O)=O)c(Br)c1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)c1ccc(C(O)=O)c(Br)c1 MZNGRBNGYVGABU-UHFFFAOYSA-N 0.000 description 2
- HCKPRYOVBPHHCR-UHFFFAOYSA-N CN1C(NC2=C1C(=CC=C2)N1CCN(CC1)C(=O)OC(C)(C)C)=O Chemical compound CN1C(NC2=C1C(=CC=C2)N1CCN(CC1)C(=O)OC(C)(C)C)=O HCKPRYOVBPHHCR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 description 2
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 description 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 2
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 description 2
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- BRGTUCHMFDHZCC-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)N1CCC(CC1)C=O)F)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)N1CCC(CC1)C=O)F)=O)=O BRGTUCHMFDHZCC-UHFFFAOYSA-N 0.000 description 2
- KJZZXYASBYEXIJ-UHFFFAOYSA-N OC(=O)Cc1ccc2C(=O)N(Cc2c1)C1CCC(=O)NC1=O Chemical compound OC(=O)Cc1ccc2C(=O)N(Cc2c1)C1CCC(=O)NC1=O KJZZXYASBYEXIJ-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 102100032783 Protein cereblon Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 2
- 239000001064 degrader Substances 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000002557 hidradenitis Diseases 0.000 description 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- JEJMDUMJSZTJTI-UHFFFAOYSA-N methyl 4,6-dichloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=C1Cl JEJMDUMJSZTJTI-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- HRVXPXCISZSDCC-UHFFFAOYSA-N piperidine-4-carbaldehyde Chemical compound O=CC1CCNCC1 HRVXPXCISZSDCC-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- JULZCRDAJLDNFW-UHFFFAOYSA-N tert-butyl 4-(3-bromo-4-methoxycarbonylphenyl)piperazine-1-carboxylate Chemical compound BrC=1C=C(C=CC=1C(=O)OC)N1CCN(CC1)C(=O)OC(C)(C)C JULZCRDAJLDNFW-UHFFFAOYSA-N 0.000 description 2
- DANIYVQIRXOIKI-UHFFFAOYSA-N tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)C1=CC2=C(C=C1)C(=O)N(C2)C1CCC(=O)NC1=O DANIYVQIRXOIKI-UHFFFAOYSA-N 0.000 description 2
- FUYBPBOHNIHCHM-UHFFFAOYSA-N tert-butyl piperidine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCNCC1 FUYBPBOHNIHCHM-UHFFFAOYSA-N 0.000 description 2
- VLFRGIAACOBTLR-UHFFFAOYSA-N tert-butyl piperidine-4-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)C1CCNCC1 VLFRGIAACOBTLR-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- PTTUMBGORBMNBN-UHFFFAOYSA-N 1,2,3-trifluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C(F)=C1 PTTUMBGORBMNBN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- NKVUYPVQGPCIJO-UHFFFAOYSA-N 1-(1h-pyrrolo[2,3-b]pyridin-5-yl)ethanone Chemical compound CC(=O)C1=CN=C2NC=CC2=C1 NKVUYPVQGPCIJO-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 1
- HRMRQBJUFWFQLX-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)C1 HRMRQBJUFWFQLX-UHFFFAOYSA-N 0.000 description 1
- AIMKHMPTWRYWQH-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carbaldehyde Chemical compound O=CC(CC1)CCN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O AIMKHMPTWRYWQH-UHFFFAOYSA-N 0.000 description 1
- TXZFWPHJZKOMQY-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carbaldehyde Chemical compound O=CC1CCN(CC1)C1=CC=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=C1 TXZFWPHJZKOMQY-UHFFFAOYSA-N 0.000 description 1
- LXOQUSNJOGMSJJ-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carboxylic acid Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)N4CCC(CC4)C(=O)O LXOQUSNJOGMSJJ-UHFFFAOYSA-N 0.000 description 1
- LSGWYFVKUCQXNZ-UHFFFAOYSA-N 1-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4-yl]methyl]piperidine-4-carboxylic acid Chemical compound OC(C1CCN(CC(CC2)CCN2C(C=CC=C2C(N3C(CCC(N4)=O)C4=O)=O)=C2C3=O)CC1)=O LSGWYFVKUCQXNZ-UHFFFAOYSA-N 0.000 description 1
- GGQOMRPVQMGZMZ-UHFFFAOYSA-N 1-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)C1CC1(N)C(O)=O GGQOMRPVQMGZMZ-UHFFFAOYSA-N 0.000 description 1
- MWYFDHRLYOKUMH-UHFFFAOYSA-N 1-bromo-2-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1F MWYFDHRLYOKUMH-UHFFFAOYSA-N 0.000 description 1
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- UEWIETUNZIVFLI-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine-5-carbonitrile Chemical group N#CC1=CN=C2NN=CC2=C1 UEWIETUNZIVFLI-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- MNHUBBRVPVSVCM-UHFFFAOYSA-N 2,5-dibromo-1,3,4-thiadiazole Chemical compound BrC1=NN=C(Br)S1 MNHUBBRVPVSVCM-UHFFFAOYSA-N 0.000 description 1
- YIBCNIAUDQMKRO-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1CCC(=O)NC1=O YIBCNIAUDQMKRO-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SZAAHQWPPBNUQR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl]-2-azaspiro[3.3]heptane-6-carboxylic acid Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(C(O)=O)C1 SZAAHQWPPBNUQR-UHFFFAOYSA-N 0.000 description 1
- QFGQEEVKWSGRQJ-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]spiro[3.3]heptane-6-carboxylic acid Chemical compound C1C(NC(=O)OC(C)(C)C)CC21CC(C(O)=O)C2 QFGQEEVKWSGRQJ-UHFFFAOYSA-N 0.000 description 1
- FGSAQRJRWCZLOB-UHFFFAOYSA-N 2-chloro-4-fluoropyridine Chemical compound FC1=CC=NC(Cl)=C1 FGSAQRJRWCZLOB-UHFFFAOYSA-N 0.000 description 1
- OFCBNMYNAHUDGE-UHFFFAOYSA-N 2-chloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1 OFCBNMYNAHUDGE-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- MNXNDLQGVDOJQY-UHFFFAOYSA-N 2-methylnonanal Chemical compound CCCCCCCC(C)C=O MNXNDLQGVDOJQY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RYSICGXZRVMXDP-UHFFFAOYSA-N 3-bromopiperidine-2,6-dione Chemical compound BrC1CCC(=O)NC1=O RYSICGXZRVMXDP-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LDMHYYGJZWDBQL-UHFFFAOYSA-N 4,5-difluoro-2-methylbenzoic acid Chemical compound CC1=CC(F)=C(F)C=C1C(O)=O LDMHYYGJZWDBQL-UHFFFAOYSA-N 0.000 description 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- UATBWQQFLABWKR-UHFFFAOYSA-N 5,6-difluoro-2-benzofuran-1,3-dione Chemical compound C1=C(F)C(F)=CC2=C1C(=O)OC2=O UATBWQQFLABWKR-UHFFFAOYSA-N 0.000 description 1
- QVADRSWDTZDDGR-UHFFFAOYSA-N 5-oxotetrahydrofuran-2-carboxylic acid Chemical compound OC(=O)C1CCC(=O)O1 QVADRSWDTZDDGR-UHFFFAOYSA-N 0.000 description 1
- ASNXCLBPISBIFU-UHFFFAOYSA-N 7-[(2-methylpropan-2-yl)oxycarbonyl]-7-azaspiro[3.5]nonane-2-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(C(O)=O)C1 ASNXCLBPISBIFU-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- XSHPTQDAPVOXCQ-UHFFFAOYSA-N BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(N(C(CC1)=O)CC1=CC=C(C=C1)OC)=O Chemical compound BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(N(C(CC1)=O)CC1=CC=C(C=C1)OC)=O XSHPTQDAPVOXCQ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000023611 Burkitt leukaemia Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- OWQDKCPCWZDBBJ-UHFFFAOYSA-N CC(C)(C)C1CN(CCN1C(=O)O)C2=CC3=C(C=C2)C(=O)N(C3)C4CCC(=O)NC4=O Chemical compound CC(C)(C)C1CN(CCN1C(=O)O)C2=CC3=C(C=C2)C(=O)N(C3)C4CCC(=O)NC4=O OWQDKCPCWZDBBJ-UHFFFAOYSA-N 0.000 description 1
- RWOSSJIMWSPDOV-UHFFFAOYSA-N CC([K])=C.FB(F)F Chemical group CC([K])=C.FB(F)F RWOSSJIMWSPDOV-UHFFFAOYSA-N 0.000 description 1
- FXUHVQUDKOJZGI-UHFFFAOYSA-N CN1C(N(C2=C1C(=CC=C2)N1CCN(CC1)C(=O)OC(C)(C)C)COCC[Si](C)(C)C)=O Chemical compound CN1C(N(C2=C1C(=CC=C2)N1CCN(CC1)C(=O)OC(C)(C)C)COCC[Si](C)(C)C)=O FXUHVQUDKOJZGI-UHFFFAOYSA-N 0.000 description 1
- WSVZTQCKRCIGKK-UHFFFAOYSA-N COC1=CC=C(CN2C(=O)CCC(OS(=O)(=O)C(F)(F)F)C2=O)C=C1 Chemical compound COC1=CC=C(CN2C(=O)CCC(OS(=O)(=O)C(F)(F)F)C2=O)C=C1 WSVZTQCKRCIGKK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940127590 IRAK4 inhibitor Drugs 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 101150102972 Irak4 gene Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229940126004 KT-474 Drugs 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- ZZVWSSILFDRGJI-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N1CCC(CC1)CO)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N1CCC(CC1)CO)=O)=O ZZVWSSILFDRGJI-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- OBBCQHYXZOIRNT-UHFFFAOYSA-N azido(nitro)cyanamide Chemical compound [O-][N+](=O)N(C#N)N=[N+]=[N-] OBBCQHYXZOIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CLPHAYNBNTVRDI-UHFFFAOYSA-N ditert-butyl propanedioate Chemical compound CC(C)(C)OC(=O)CC(=O)OC(C)(C)C CLPHAYNBNTVRDI-UHFFFAOYSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- KGZLFTWMCMEEJR-UHFFFAOYSA-N heptane;hydrochloride Chemical compound Cl.CCCCCCC KGZLFTWMCMEEJR-UHFFFAOYSA-N 0.000 description 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004246 indolin-2-yl group Chemical group [H]N1C(*)=C([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004704 methoxides Chemical class 0.000 description 1
- JENBPOJAZCPSEW-UHFFFAOYSA-N methyl 2-bromo-4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1Br JENBPOJAZCPSEW-UHFFFAOYSA-N 0.000 description 1
- CYEXEOXALMJXDI-UHFFFAOYSA-N methyl 4-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1C CYEXEOXALMJXDI-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- IYSNYCQLARBERC-UHFFFAOYSA-N methylsulfinylmethane;toluene Chemical class CS(C)=O.CC1=CC=CC=C1 IYSNYCQLARBERC-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- NRADOPGBTAJXKB-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical group C1CN(C(=O)OC(C)(C)C)CCC11CNC1 NRADOPGBTAJXKB-UHFFFAOYSA-N 0.000 description 1
- MUQCFFHJAVVMHO-UHFFFAOYSA-N tert-butyl 2-(5-bromo-1,3,4-thiadiazol-2-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CN(C=2SC(Br)=NN=2)C1 MUQCFFHJAVVMHO-UHFFFAOYSA-N 0.000 description 1
- WWFJYZONBJARJT-UHFFFAOYSA-N tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=N1 WWFJYZONBJARJT-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention requires an invention patent application submitted in China on March 31, 2022, titled “A class of bifunctional chimeric heterocyclic compounds of interleukin-1 receptor-related kinases and their preparation methods and uses” and the application number is 202210334860.3 And priority is given to the invention patent application submitted in China on September 28, 2022, titled “A class of bifunctional chimeric heterocyclic compounds of interleukin-1 receptor-related kinases and their preparation methods and uses” with application number 202211214397.5 The entire contents of the above patent application are incorporated herein by reference.
- the invention belongs to the field of medical technology. Specifically, the invention relates to a bifunctional chimeric heterocyclic compound of interleukin-1 receptor-associated kinase 4 (IRAK4) and its preparation method, pharmaceutical composition and use.
- IRAK4 interleukin-1 receptor-associated kinase 4
- Interleukin-1 receptor-associated kinase 4 belongs to the IRAK family (including IRAK1, IRAK2, IRAK3 and IRAK4). It is encoded by the IRAK4 gene and is located on chromosome 12. As a threonine/serine protein kinase, IRAK4 consists of 460 amino acids, contains a kinase domain and a death domain, and has high homology with IRAK1, IRAK2, IRAK3 (IRAKM) and Pelle kinase. IRAK4 is the most unique member of the family in that it lacks a C-terminal domain and functions upstream of other members. IRAK4 is expressed in multiple tissues of the human body, but is mainly distributed in liver and lung tissues.
- IRAK4 is a key regulator downstream of the interleukin-1 receptor (IL-1R) and toll-like receptors (TLRs) signaling pathways. It causes the transcription and expression of pro-inflammatory cytokine genes through the IL-1R/TLRs signaling pathway, triggering the innate immune response. Abnormal IL-1R/TLRs conduction is involved in a variety of autoimmune diseases, so IRAK4 has become a target of autoimmune diseases. An effective target; and MyD88 serves as a key regulator of the IL-1R/TLRs signaling pathway, making IRAK4 play an important role in tumors with MyD88 mutations.
- IL-1R interleukin-1 receptor
- TLRs toll-like receptors
- IL-1R/TLRs receptors In the innate immune response, both IL-1R/TLRs receptors rely on MyD88 as a regulator to activate downstream inflammatory signaling pathways.
- MyD88 factor When IL-1R/TLRs and ligands recruit MyD88 factor, MyD88 factor forms a dimer and further recruits IRAK4 through its N-terminal death domain.
- IRAK4 exerts kinase activity through autophosphorylation and activates the substrate IRAK1, and IRAK1 then It undergoes a conformational change and forms a complex with TNF receptor-associated factor 6 (TRAF6).
- TNF receptor-associated factor 6 TNF receptor-associated factor 6
- TRAF6 activates NF- ⁇ B through the adapter protein TAK1, etc., causing the activated NF- ⁇ B to enter the nucleus and cause the transcription and expression of pro-inflammatory cytokine genes.
- TRAF6 can also activate p38 and JNK, thereby activating the AP1 pathway.
- IRAK4 overexpression can enhance the activity of LPS-induced NADPH oxidase, thereby affecting downstream MAPK signaling. Therefore, IRAK4 can trigger inflammatory responses through multiple pathways such as IRAK1/TRAF6/NF- ⁇ B/AP1 and NADPH/MAPK/AP1.
- IRAK4 as a degradation target can provide new treatment options for the treatment of autoimmune diseases, inflammation and tumor-related diseases.
- IRAK4 protein degradation targeting chimeras
- TPD target protein degradation
- thalidomide derivatives, lenalidomide and pomalidomide can recruit protein substrates to a ubiquitin ligase complex called cereblon (CRBN) to degrade the protein substrates.
- CRBN cereblon
- KT-474 SAR444656
- KT-413 PROTAC bifunctional small molecules developed by Kymera Therapeutics are in clinical phase I as oral and intravenous IRAK4 degraders respectively.
- Some of the company's other PROTAC bifunctional small molecules see WO2020264499A1, WO2020113233A1 and WO2022027058A1 also showed good PK and PD in animal experiments.
- IRAK4 inhibitor PF-06650833 (see WO2015150995A1) developed by Pfizer has a therapeutic effect on autoimmune diseases such as rheumatoid arthritis and lupus erythematosus, and is currently in clinical phase II.
- the object of the present invention is to provide a bifunctional chimeric heterocyclic compound that acts as a degradation product of IRAK4 through the ubiquitin proteasome pathway, as well as its pharmaceutical composition, preparation method and use.
- n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, C 6-12 aryl, 5-12 membered heteroaryl, amino or -OC 1 -6 alkyl; wherein, the C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, C 6-12 aryl, 5-12 membered heteroaryl, -OC 1-6 alkyl can be substituted by one or more F atoms;
- L represents -L 1 -L 2 -L 3 -L 4 -L 5 -, wherein L 1 , L 2 , L 3 , L 4 and L 5 are each independently selected from the group consisting of bonds, C 3-12 cycloalkyl, C 6-12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, -OC 2 -12 alkenylene, -OC 2-12 Alkynylene, -C(O)-, -C(O)-(CH 2 ) n -, -C(O)O-, -O-, -N(R b )-, -N(R b ) -(CH 2 ) n -, -S-, -C(S)-, -C(S)-O-, -S(O) 2 -, -S(O)(R b )
- Each R c2 is independently selected from halogen, oxo, cyano, hydroxyl, C 1-6 alkyl, C 3-8 cycloalkyl or -OC 1-6 alkyl; wherein, the C 1-6 Alkyl, -OC 1-6 alkyl can be substituted by 1-3 F atoms;
- Each R d is independently selected from halogen, oxo, cyano, hydroxyl, C 1-6 alkyl, C 3-8 cycloalkyl or -OC 1-6 alkyl; wherein, the C 1-6 Alkyl, -OC 1-6 alkyl can be substituted by 1-3 F atoms;
- R g is selected from C 1-6 alkyl or C 4-12 cycloalkyl
- R h is selected from hydrogen, C 1-6 alkyl, C 4-6 cycloalkyl, C 6-8 aryl, 4-11 membered heterocyclyl or 5-8 membered heteroaryl;
- n and p are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
- LBM is the ligase binding moiety.
- X and Z 1 are each independently selected from CH or N;
- Z 2 is selected from O or S
- Ring A and Ring B are each independently selected from 3-12-membered heterocyclyl, C 6-14 aryl or 5-12-membered heteroaryl, and the heterocyclyl and heteroaryl have 1-4 independent choices.
- Each R 1 is independently selected from hydrogen, cyano, C 1-6 alkyl, halogen, -NO 2 , -OR a1 , -SR a1 , -N(R a1 ) 2 , -S(O) 2 R a1 , -S(O) 2 N(R a1 ) 2 , -S(O)R a1 , -S(O)(NR a1 )R a1 , -P(O)(OR a1 ) 2 , -P(O )(N(R a1 ) 2 ) 2 , -CF 2 (R a1 ), -CF 3 , -CR 2 (OR a1 ), -CR 2 (N(R a1 ) 2 ), -C(O)R a1 , -C(O)OR a1 , -C(O)N(R a1 ) 2 , -C(O)N(R
- n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
- Each R a1 is independently selected from hydrogen, C 1-6 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, phenyl, C 4-7 cycloalkyl, C 3-6 cycloalkenyl , 4-7-membered heterocycloalkyl or 5-6-membered heteroaryl; wherein, the heterocycloalkyl or heteroaryl has 1-4 heteroatoms selected from N, O, and S;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, C 6-12 aryl, 5-12 membered heteroaryl, amino or -O C 1 -6 alkyl; wherein, the C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, C 6-12 aryl, 5-12 membered heteroaryl, -OC 1-6 alkyl groups may be substituted by one or more fluorine atoms;
- R b is selected from hydrogen or C 1-6 alkyl
- Each R c1 is independently selected from H or C 1-6 alkyl
- R g is selected from C 1-6 alkyl or C 4-12 cycloalkyl
- n and p are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
- the ring A and ring B are each independently selected from partially saturated 4-6-membered heterocyclyl, 5-6-membered heteroaryl or C 6-8 aryl.
- ring A is selected from partially saturated 5-membered heterocyclyl or 5-membered heteroaryl
- ring B is selected from phenyl or 6-membered heteroaryl
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are:
- the ring A and ring B formed together are selected from:
- the ring A and ring B formed together are selected from:
- each R 1 is independently selected from hydrogen, cyano, C 1-6 alkyl, halogen, hydroxyl, amino, -C(O)C 1-6 alkyl , -COOH, -C(O)OC 1-6 alkyl, -C(O)NH 2 , -C(O)N(C 1-6 alkyl) 2 or 7-9 membered heterocycloalkyl; m Choose from 0, 1 or 2.
- each R 1 is independently selected from hydrogen, cyano, methyl, ethyl, n-propyl, isopropyl, F, Cl, Br, hydroxyl, amino, -C(O)CH 3 , -C(O)CH 2 CH 3 , -COOH, -C(O)OCH 2 CH 3 , -C(O)OCH 3 , -C(O)NH 2 , -C( O)N(CH 3 ) 2- or 7-membered heterocycloalkyl; m is selected from 0 or 1.
- each R 1 is independently selected from hydrogen, cyano, methyl, F, hydroxyl, amino, -C(O)NH 2 or 7-membered heterocycloalkyl; m is chosen from 0 or 1.
- each R 1 is independently selected from hydrogen, cyano, C 1-6 alkyl, halogen, hydroxyl, amino, -C(O)C 1-6 alkyl , -COOH, -C(O)OC 1-6 alkyl, -C(O)NH 2 , -C(O)N(C 1-6 alkyl) 2 ; m is selected from 0, 1 or 2.
- each R 1 is independently selected from hydrogen, cyano, methyl, ethyl, n-propyl, isopropyl, F, Cl, Br, hydroxyl, amino, -C(O)CH 3 , -C(O)CH 2 CH 3 , -COOH, -C(O)OCH 2 CH 3 , -C(O)OCH 3 , -C(O)NH 2 , -C( O)N(CH 3 ) 2 ; m is selected from 0 or 1.
- each R 1 is independently selected from hydrogen, cyano, methyl, F, hydroxyl, amino, -C(O)NH 2 , -C(O)N( CH 3 ) 2 ; m is selected from 0 or 1.
- said R 1 is selected from 7-9 membered heterocycloalkyl.
- said R 1 is selected from 7-membered heterocycloalkyl.
- said R 1 is selected from
- the R 2 is selected from hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, C 6-12 aryl, 5 -12-membered heteroaryl, amino or -OC 1-6 alkyl.
- the R 2 is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, amino or methoxy.
- Each R d is independently selected from halogen, oxo, cyano, hydroxyl, C 1-6 alkyl, C 3-8 cycloalkyl or -OC 1-6 alkyl; wherein, the C 1-6 alkyl Base, -OC 1-6 alkyl group can be substituted by 1-3 fluorine atoms;
- L represents -L 1 -L 2 -L 3 -L 4 -L 5 -, wherein L 1 , L 2 , L 3 , L 4 and L 5 are each independently selected from bond, C 4-6 cycloalkyl, C 6-8 aryl, 4-11 membered heterocyclyl, 5-8 membered heteroaryl, C 1-3 alkylene, C 2-4 alkenylene, C 2-4Alkynylene , -C(O)-, -C(O)O-, -O-, -N(R b )-, -N(R b )-(CH 2 ) 2 - or -C (O)-N(R b )-; R b is selected from hydrogen or C 1-6 alkyl.
- L represents -L 1 -L 2 -L 3 -L 4 -L 5 -, where L 5 is connected to LBM, and L 1 , L 2 , L 3 , L 4 and L 5 is each independently selected from bond, C 3-11 cycloalkyl, 3-12 membered heterocyclyl, C 1-6 alkylene, C 2-8 alkenylene, C 2-8 alkynylene, - OC 2-8 alkenylene, -OC 2-8 alkynylene, -C(O)-, -C(O)-(CH 2 ) n -, -O-, -N(R b )-, - N(R b )-(CH 2 ) n -, -C(O)-N(R b )-, -(CH 2 ) n -C(O)-N(R b )-, -(CH 2 ) n -C(O)-N(R b )-, -
- L 4 is selected from bond, C 1-3 alkylene, -C(O)- or -C(O)-(CH 2 ) n -;
- L 3 is selected from a bond or a 5-10 membered heterocyclic group
- L 5 is selected from bond, 5-6 membered heterocyclyl, C 1-3 alkylene, C 2-4 alkynylene, -N(R b )-(CH 2 ) n -, -OC 2-4 Alkynyl or -C(O)-(CH 2 ) n -;
- n is selected from 0, 1, 2 or 3.
- L 2 is selected from C 1-3 alkylene, -C(O)-NH-, -C(O)-, -C(O)-(CH 2 ) n -, -(CH 2 ) n -C( O)-N(R b )-, -N(R b )-(CH 2 ) n -or 5-6 membered heterocyclyl;
- L 5 is selected from bond, 5-6 membered heterocyclyl, methylene, ethylene, n-propylene, ethynylene, propynylene, butynylene, -N(R b )-(CH 2 ) n -, -O-ethynylene, -O-propynylene or -C(O)-(CH 2 ) n -;
- R b is selected from hydrogen, methyl or ethyl
- said L is selected from the structure shown below and its stereoisomers:
- said L is selected from the structure shown below and its stereoisomers:
- the LBM is a compound of formula (II):
- R h is selected from hydrogen, C 1-6 alkyl, C 4-6 cycloalkyl, C 6-8 aryl, 4-11 membered heterocyclyl or 5-8 membered heteroaryl.
- the LBM is a compound of formula (II), wherein,
- Each R f2 is independently selected from halogen, oxo, cyano, hydroxyl, C 1-6 alkyl, C 3-8 cycloalkyl or -OC 1-6 alkyl, wherein said C 1-6 alkyl Base, -OC 1-6 alkyl group can be substituted by 1-3 fluorine atoms;
- Rg is selected from C 1-6 alkyl, C 4-12 cycloalkyl
- R h is selected from hydrogen, C 1-6 alkyl, C 4-6 cycloalkyl, C 6-8 aryl, 4-11 membered heterocyclyl or 5-8 membered heteroaryl;
- the LBM is a compound of formula (IIa):
- R e is selected from hydrogen or C 1-6 alkyl
- Each R f is independently selected from halogen, nitro, cyano, hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl or -OC 1-4 alkyl;
- q is selected from 0, 1, 2 or 3.
- the LBM is a compound of formula (IIa'):
- Each R f is independently selected from halogen, nitro, cyano, hydroxyl, C 1-3 alkyl, C 1-3 haloalkyl or -OC 1-4 alkyl; preferably, R f is selected from halogen, Nitro, cyano, hydroxyl, C 1-3 alkyl, C 1-3 haloalkyl or -OC 1-4 alkyl;
- q is selected from 0, 1, 2 or 3.
- the LBM is a compound of formula (IIa'), wherein,
- q is chosen from 0 or 1.
- the LBM is selected from:
- the LBM is a compound of formula (IIb):
- W is selected from C( Re ) or N;
- R e is selected from hydrogen or C 1-6 alkyl
- Each R f is independently selected from F, Cl, Br, nitro, cyano, hydroxyl, methyl or methoxy;
- the LBM is a compound of formula (IIb') or a compound of formula (IIb"),
- R f is F.
- the LBM is a compound of formula (IIb'):
- the LBM is selected from:
- the LBM is selected from:
- the LBM is a compound of formula (IIc):
- W is selected from C( Re ) or N;
- R e is selected from hydrogen or C 1-6 alkyl
- Each R i1 is independently selected from hydrogen or C 1-6 alkyl
- Each R i2 is independently selected from halogen, oxo, cyano, hydroxy, C 1-6 alkyl, C 3-8 cycloalkyl or -OC 1-6 alkyl, wherein said C 1-6 alkyl Base, -OC 1-6 alkyl group can be substituted by 1-3 fluorine atoms;
- Rg is selected from C 1-6 alkyl, C 4-12 cycloalkyl
- the LBM is a compound of formula (IIc-1):
- W, Y 1 and Y 2 are each independently selected from CH or N.
- the LBM is:
- the LBM is a compound of formula (IIc-2):
- W and Y 2 are each independently selected from CH or N;
- the LBM is:
- the LBM is a compound of formula (IIc-3):
- W, M 2 and M 3 are independently selected from CH or N; M 1 is selected from O or S;
- Ri can be selected from methyl, ethyl, n-propyl, isopropyl, F, Cl, nitro, cyano, hydroxyl or methoxy.
- the LBM is a compound of formula (IIc-3'):
- W is selected from CH or N; Ri can be selected from methyl, ethyl, n-propyl, isopropyl, F, Cl, hydroxyl or methoxy.
- W is selected from CH or N; Ri can be selected from methyl, ethyl, n-propyl, isopropyl, F, Cl, hydroxyl or methoxy.
- the LBM is selected from:
- the LBM is a compound of formula (IIc-4):
- W, M 2 and M 3 are independently selected from CH or N;
- M 1 is selected from O or S.
- W, M 2 and M 3 are independently selected from CH or N.
- the LBM is:
- the LBM is a compound of formula (IIc-5):
- W and M 4 are independently selected from CH or N;
- X 1 is selected from O or S
- X 2 is selected from CH or N
- X 3 is selected from C
- Rf is selected from hydrogen, halogen, cyano, hydroxyl, methyl, ethyl, n-propyl or isopropyl.
- the LBM is a compound of formula (IIc-5'):
- the LBM is a compound of formula (IIc-5′′):
- Rf is selected from hydrogen, methyl, ethyl, n-propyl or isopropyl.
- the LBM is a compound of formula (IIc-6):
- the LBM is a compound of formula (IId):
- W is selected from CH or N;
- W 1 Represents a single bond or a double bond, when When representing a single bond, W 1 is selected from CH 2 or NH, when When representing a double bond, W 1 is selected from CH or N;
- the LBM is a compound of formula (IId), wherein,
- W is selected from CH or N;
- the LBM is a compound of formula (IId'):
- the LBM is a compound of formula (II), wherein,
- W, W 1 is selected from CH or N;
- Each R f is independently selected from halogen, nitro, cyano, hydroxy, methyl, ethyl, n-propyl, or isopropyl.
- Cy2 is selected from phenyl, pyridine, pyrazole, imidazole, thiazole or pyrrole, wherein the phenyl, pyridine, pyrazole, imidazole, thiazole or pyrrole can be substituted by 1-2 R f ;
- Each R f is independently selected from F, Cl, bromine, nitro, cyano, hydroxy or methyl.
- the LBM is:
- the LBM is a compound of formula (IIIa) or a compound of formula (IIIb):
- ring A, ring B, R 1 , m, R 2 , X, Z 1 , L and LBM are as described for the compound of formula (I) above.
- ring A is selected from 5-membered heterocyclyl or 5-membered heteroaryl
- ring B is selected from phenyl or 6-membered heteroaryl
- R 2 is selected from hydrogen, C 1-3 alkyl, amino or methoxy.
- R 1 , m, R 2 , L and LBM are as defined in the compound of formula (I) above.
- R 1 is selected from hydrogen, cyano, methyl, F, Cl, hydroxyl, amino, -C(O)CH 3 , - C(O)NH 2 , -C(O)N(CH 3 ) 2 or 7-9 membered heterocycloalkyl;
- n is selected from 0, 1 or 2;
- the invention provides compounds having the following structures, and stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotopic labels thereof:
- the present invention also provides a pharmaceutical composition, which contains the compound of the present invention or its stereoisomer, optical isomer, pharmaceutically acceptable salt, prodrug, solvate or isotope label.
- the present invention also provides a pharmaceutical composition, which contains the compound of the present invention or its stereoisomer, optical isomer, pharmaceutically acceptable salt, prodrug, solvate or isotope label, and a pharmaceutically acceptable of excipients.
- the object of the present invention also includes providing the compound of the present invention or its stereoisomer, optical isomer, pharmaceutical salt, prodrug, solvate or isotope label or the pharmaceutical combination of the present invention.
- the compounds of the present invention or their stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotope labels or the pharmaceutical compositions of the present invention are used in the preparation of prevention and/or treatment of It can be used alone or in combination with other pharmaceutical active ingredients when treating IRAK4-mediated diseases, disorders or conditions.
- the object of the present invention also includes providing a method for degrading and/or inhibiting IRAK protein kinase (preferably IRAK4) in a patient or biological sample, which includes administering to the patient a compound of the present invention or a stereoisomer thereof , optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotope labels or the pharmaceutical compositions of the present invention, or the biological sample and the compounds of the present invention or their stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotopic labels or pharmaceutical compositions of the invention.
- IRAK protein kinase preferably IRAK4
- the compounds of the present invention or their stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotope labels or the pharmaceutical compositions of the present invention degrade and/or inhibit patients or biological samples.
- IRAK protein kinase preferably IRAK4
- it can be used alone or in combination with other drugs.
- the object of the present invention also includes providing a method for preventing and/or treating diseases, disorders or conditions mediated by IRAK4, which includes administering to the patient a preventive and/or therapeutically effective dose of a compound of the present invention or Its stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotope labels or the pharmaceutical composition of the present invention.
- the compounds of the present invention or their stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotope labels or the pharmaceutical compositions of the present invention are used in the prevention and/or treatment of IRAK4-mediated It may be used alone or in combination with other medicines to treat a disease, disorder or condition.
- the object of the present invention also includes providing the compound of the present invention or its stereoisomer, optical isomer, pharmaceutically acceptable salt, prodrug, solvate or isotope label or the pharmaceutical composition of the present invention. , for the prevention and/or treatment of diseases, disorders or conditions mediated by IRAK4.
- the disease, disorder or condition mediated by IRAK4 is cancer, neurodegenerative disease, viral disease, autoimmune disease, inflammatory disorder, genetic disorder, hormone-related disease, metabolic disease Disorders, conditions related to organ transplantation, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, conditions related to cell death, thrombin-induced platelet aggregation, liver disease, pathological immunity involving T cell activation medical condition, cardiovascular disease, or central nervous system (CNS) disease disease.
- cancer neurodegenerative disease, viral disease, autoimmune disease, inflammatory disorder, genetic disorder, hormone-related disease, metabolic disease Disorders, conditions related to organ transplantation, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, conditions related to cell death, thrombin-induced platelet aggregation, liver disease, pathological immunity involving T cell activation medical condition, cardiovascular disease, or central nervous system (CNS) disease disease.
- CNS central nervous system
- the cancer includes: benign or malignant tumors, solid tumors, brain cancer, kidney cancer, liver cancer, adrenal cancer, bladder cancer, breast cancer, gastric cancer, gastric tumors, ovarian cancer, colon cancer, rectum Cancer, prostate cancer, pancreatic cancer, lung cancer, vaginal cancer, cervical cancer, testicular cancer, genitourinary tract cancer, esophageal cancer, laryngeal cancer, skin cancer, bone cancer, thyroid cancer, sarcoma, glioblastoma, neuroblastoma Neoplasms, multiple myeloma, gastrointestinal cancer, colorectal adenomas, tumors of the neck and head, epidermal hyperplasia, prostatic hyperplasia, neoplasia, neoplasia with epithelial features, adenoma, adenocarcinoma, keratoacanthoma , epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lympho
- the hematological malignancies include: leukemia, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion Lymphoma, Burkitt's lymphoma/leukemia, acute lymphoblastic leukemia, B-cell prelymphoblastic leukemia, lymphoplasmacytic lymphoma, Waldenström's macroglobulinemia (WM), splenic marginal zone lymphoma neoplasia, multiple myeloma, plasmacytoma or intravascular large B-cell lymphoma, Waldenström's macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma, and indolent multiple Myeloma.
- LLBCL diffuse large B-cell lymphoma
- CLL chronic lymphocytic leukemia
- chronic lymphocytic lymphoma primary effusion Lymphoma
- the neurodegenerative diseases include: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia and those caused by traumatic injury, trough Neurodegenerative diseases caused by amino acid neurotoxicity, hypoxia, epilepsy, diabetes treatment, metabolic syndrome, obesity, organ transplantation, and graft-versus-host disease;
- the inflammatory disorders include: ocular allergies, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, allergic rhinitis; hemolytic anemia, aplastic anemia, pure red blood cell anemia, special Idiopathic thrombocytopenia or other diseases in which an autoimmune reaction is involved or has an autoimmune component or cause: systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's disease, dermatitis Myositis, chronic active hepatitis, myasthenia gravis, Steven Johnson syndrome, idiopathic steatorrhea, ulcerative colitis, Crohn's disease or other autoimmune inflammatory bowel disease, irritable bowel syndrome , Celiac disease, periodontitis, hyaline membrane disease, nephropathy, glomerular disease, alcoholic liver disease, endoc
- the present invention also provides the following two general preparation methods of the compounds of the present invention:
- compound I-a2 can be obtained;
- compound I-a3 can be obtained;
- compound I-a3 and carboxylic acid are used as basic raw materials, and compound I-a4 is obtained by reaction;
- compound I-a4 reacts with Lawson's reagent to obtain compound I-a5;
- compound I of the general formula can be obtained through reactions such as condensation and reductive amination.
- compound I-b2 can be obtained;
- compound I-b3 can be obtained;
- compound I-b3 and pinacol borate are used as basic raw materials, and compound I-b4 is obtained by reaction;
- compound I-b4 and I-b5 undergo a coupling reaction to obtain compound I-b6;
- compound I of the general formula can be obtained through reactions such as condensation and reductive amination.
- the present invention also provides compounds of formula (III) or their stereoisomers, optical isomers, pharmaceutically acceptable salts, prodrugs, solvates or isotopic labels that can be used as E3 ligands:
- W, M 2 and M 3 are each independently selected from CH or N;
- R 12 is selected from hydrogen, halogen (preferably F, Cl or Br), tert-butoxycarbonyl, benzyl, benzyloxycarbonyl, -CH 2 -tert-butoxycarbonyl, -CH 2 COOH, - COC 1-3 alkyl or C 1-3 alkyl;
- R 12 is selected from hydrogen, tert-butoxycarbonyl, benzyl, benzyloxycarbonyl, -CH 2 -tert-butoxycarbonyl, -CH 2 COOH, -COC 1-3 alkyl or C 1- 3 alkyl;
- M 1 is selected from O or S
- Ri is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, F, Cl, nitro, cyano, hydroxyl or methoxy.
- the compound of formula (III) is a compound of formula (III'):
- R 12 is selected from hydrogen, tert-butoxycarbonyl, -CH 2 -tert-butoxycarbonyl, -CH 2 COOH or -COCH 3 ;
- W is selected from CH or N;
- Ri is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, F, Cl, hydroxyl or methoxy.
- the compound of formula (III) is a compound of formula (III") or a compound of formula (III"'):
- W is selected from CH or N;
- Ri is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, F, Cl, hydroxyl or methoxy.
- R 12 is selected from hydrogen, tert-butoxycarbonyl, -CH 2 -tert-butoxycarbonyl, -CH 2 COOH or -COCH 3 .
- R 13 is selected from hydrogen, halogen, amino, hydroxyl, tert-butoxycarbonyl, -CH 2 -tert-butoxycarbonyl, -NH-tert-butoxycarbonyl, -NH-benzyl, -NH-benzyloxycarbonyl, -CH 2 COOH, -COC 1-3 alkyl, C 1-3 alkyl, C 1-3 alkoxy, C 3-12 cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 aryl, 5 -14-membered heteroaryl or 3-14-membered heterocyclyl;
- W and M 4 are each independently selected from CH or N;
- Rf is selected from hydrogen, methyl, ethyl, n-propyl or isopropyl.
- the compound of formula (IV) is a compound of formula (IV'):
- the compound of formula (IV) is selected from:
- Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, but are not limited to, triazacyclohexyl, oxadiazinyl, thiadiazinyl, oxothiazinyl, and dioxa Dioxazinanyl.
- Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azepanyl, oxpanyl, and thiepanyl.
- Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, but are not limited to, tetrahydroquinolyl, tetrahydroisoquinolyl wait.
- Exemplary structures of ring systems in which the heterocyclyl ring is fused with one or more carbocyclyl or heteroaryl groups include, but are not limited to, the following structures:
- It preferably contains 3 to 14 ring atoms ("3-14 membered heterocycloalkyl”), more preferably contains 3 to 12 ring atoms (“3-12 membered heterocycloalkyl”), and further preferably contains 3 to 10 ring atoms.
- Ring atoms ("3-10 membered heterocycloalkyl"), more preferably contain 3 to 8 ring atoms ("3-8 membered heterocycloalkyl"), or even more preferably contain 3 to 7 ring atoms ( "3-7 membered heterocycloalkyl"), or more preferably contains 4-8 ring atoms ("4-8 membered heterocycloalkyl"), or even more preferably contains 4-7 ring atoms ("4 -7-membered heterocycloalkyl”), or more preferably contains 5 to 10 ring atoms ("5-10 membered heterocycloalkyl"), or even more preferably contains 5 to 6 ring atoms ("5- 6-membered heterocycloalkyl”).
- Heterocycloalkyl also includes bridged (“heterobridged cycloalkyl” or “bridged cycloheterocycloalkyl”) or spiro-fused (“heterospirocycloalkyl” or “spirocycloheterocycloalkyl”). ”) ring system, and may be saturated or partially unsaturated. Based on the above heterocycloalkyl, 7-9 membered heterocycloalkyl is preferred, and 7-membered heterocycloalkyl is further preferred. Examples Structures include but are not limited to the following structures:
- aryl or "aromatic ring group” means a group containing 6 to 16 carbon atoms (C 6-16 aryl), or 6 to 14 carbon atoms (C 6-14 aryl), Or a monocyclic ring of 6-12 carbon atoms (C 6-12 aryl), or 6-10 carbon atoms (C 6-10 aryl), or 6-8 carbon atoms (C 6-8 aryl),
- aryl may be used interchangeably with the term "aromatic ring”. Examples of aryl groups may include phenyl, naphthyl, anthracenyl, phenanthrenyl or pyrenyl, and the like.
- alkenyl refers to a linear or branched monovalent unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond.
- the alkenyl group may contain 2-20 carbon atoms, preferably 2-12 carbon atoms (i.e. C 2-12 alkenyl), more preferably 2-10 carbon atoms (i.e. C 2-10 alkenyl), further preferably Contains 2-8 carbon atoms (C 2-8 alkenyl), more preferably 2-6 carbon atoms (ie C 2-6 alkenyl), 2-5 carbon atoms (ie C 2-5 alkenyl ), 2-4 carbon atoms (i.e.
- alkenyl means that the group is an alkenyl group and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6).
- alkenyl groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.
- alkylene (which is used interchangeably with “alkylene chain”) alone or in combination refers to a straight or branched divalent saturated hydrocarbon radical composed of carbon and hydrogen atoms. group.
- Cx-y alkylene (x and y are each an integer) refers to a linear or branched alkylene group containing x to y carbon atoms, including C 1 - 30 alkylene, preferably C 1 -15 alkylene, C 1-12 alkylene, C 1-8 alkylene, C 1-6 alkylene, C 1-5 alkylene, C 1-4 alkylene, C 1-3 alkylene.
- Representative examples include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, isopentylene , neopentylene, tepentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tenylene Tetraalkyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, hexadecyl, eicosyl Dialkyl, tritricoylene, tetradecylethylene, pentadecylethylene, hexadecylethylene, heptadecylethylene, octadecy
- alkylene group is optionally substituted, and the substituent is preferably one or more selected from hydroxyl, amino, mercapto, halogen, cyano, C 1-3 alkyl, C 1- 3 Substituents of alkoxy, trifluoromethyl, heterocyclyl or combinations thereof.
- alkynylene used alone or in combination refers to a group having one or more carbon-carbon triple bonds containing 2 to 12 (C 2-12 alkynylene), preferably 2 to 8 ( C 2-8 alkynylene), more preferably 2 to 6 (C 2-6 alkynylene), even more preferably 2 to 4 (C 2-4 alkynylene) carbon atoms in a straight or branched chain.
- Valent hydrocarbon group examples include, but are not limited to, ethynylene, 1-propynylene, 1-butynylene, and 1,3-butadinylene.
- alkenylene used alone or in combination refers to a group having one or more carbon-carbon double bonds containing 2 to 12 (C 2-12 alkenylene), preferably 2 to 8 ( C 2-8 alkenylene), more preferably 2 to 6 (C 2-6 alkenylene), even more preferably 2 to 4 (C 2-4 alkenylene) carbon atoms, straight or branched. Valent hydrocarbon group.
- cycloalkenyl means composed of the subgroups monocyclic hydrocarbon ring, bicyclic hydrocarbon ring or spiro-hydrocarbon ring, however, the system is unsaturated, that is, there is at least one carbon-carbon double bond but no aromatic sex.
- oxo or "oxo group” means that two H's at the same substitution position are replaced by the same O to form a double bond.
- pharmaceutically acceptable salts and “pharmaceutically acceptable salts” refer to salts that are suitable for contact with mammalian (especially human) tissue without excessive toxicity, irritation, or allergy within the scope of reasonable medical judgment. Reactions, etc., and are commensurate with a reasonable benefit/risk ratio, such as pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art.
- solvate means the physical association of a compound of the invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain circumstances, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, solvates will be able to be separated.
- the solvent molecules in a solvate may exist in regular and/or disordered arrangements. Solvates may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate” encompasses both solution phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methoxides, and isopropoxides. Solvation methods are well known in the art.
- isotopically labeled analogue refers to a molecule in a compound that is isotopically labeled, thereby providing an isotopically labeled analogue that may have improved pharmacological activity.
- Isotopes commonly used as isotope labels include: hydrogen isotopes: deuterium ( 2H ) and tritium ( 3H ); carbon isotopes: 11C , 13C and 14C ; chlorine isotopes: 35Cl and 37Cl ; fluorine isotopes: 18F ; Iodine isotopes: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; Oxygen isotopes: 15 O, 17 O and 18 O; and, sulfur isotope 35 S.
- isotopically labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues.
- deuterium and carbon 13 C are more widely used because they are easy to label and detect.
- Isotopically labeled compounds generally start from labeled starting materials and are synthesized using known synthetic techniques as for non-isotopically labeled compounds.
- the compounds of the present invention include isotopic labels, such as deuterated compounds. In some embodiments of the invention, the isotopic label of the compound is its deuterated form.
- optical isomers refers to substances with identical molecular structures and similar physical and chemical properties, but different optical rotations.
- stereoisomer refers to compounds that have the same chemical structure but different arrangements of atoms or groups in space.
- Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans) isomers, atropisomers, etc. Any resulting mixture of stereoisomers may be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on differences in the physicochemical properties of the components, for example, by chromatography. method and/or fractional crystallization method.
- the structural formulas described in the present invention include all isomeric forms (such as enantiomers, diastereomers, and geometric isomers (or conformational isomers)): for example, those containing asymmetric centers R, S configuration, double bond (Z), (E) isomers, and (Z), (E) conformational isomers. Therefore, individual stereochemical isomers or mixtures of enantiomers, diastereomers, or geometric isomers (or conformational isomers) of the compounds of the present invention are within the scope of the present invention.
- prodrug refers to a drug that is converted in the body to the parent drug.
- Prodrugs are often useful because, in some cases, they may be easier to administer than the parent drug. For example, they are bioavailable via oral administration, whereas the parent body is not.
- Prodrugs also have increased solubility in pharmaceutical compositions compared to the parent drug.
- An example of a prodrug, but not limited thereto, may be any compound of formula (I) administered as an ester ("prodrug") to facilitate delivery across cell membranes, where water solubility is detrimental to mobility, but Once the water-soluble substance is beneficial within the cell, it is subsequently metabolized and hydrolyzed into carboxylic acids, the active entities.
- Another example of a prodrug may be a short peptide (polyamino acid) bound to an acid group, where the peptide is metabolized to reveal the active moiety.
- the term "optionally substituted” means that the hydrogen at the substitutable position of the group is unsubstituted or substituted by one or more substituents, which substituents are preferably selected from the group consisting of: Group: halogen, hydroxyl, mercapto, cyano, nitro, amino, azide, oxo, carboxyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 1- 6 alkoxy group, C 3-10 cycloalkyl group, C 3-10 cycloalkylsulfonyl group, 3-10 membered heterocycloalkyl group, C 6-14 aryl group or 5-10 membered heteroaryl ring group, wherein, The C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-10 cycloalkylsulfonyl, 3 -10-membered
- the starting materials in the embodiments of the present invention are known and can be purchased on the market, or can be synthesized using or according to methods known in the art.
- Step 1 Synthesis of methyl 6-chloro-4-(methylamino)nicotinate
- Step 2 Synthesis of 6-chloro-4-(methylamino)nicotinic acid hydrazide
- Step 3 Synthesis of tert-butyl ((1r,4r)-4-(2-(6-chloro-4-(methylamino)nicotinoyl)hydrazinecarbonyl)cyclohexyl)carbamate
- Step 4 tert-Butyl((1r,4r)-4-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl) )Synthesis of cyclohexyl)carbamate
- reaction system was poured into water (500 mL), extracted with DCM (400 mL ⁇ 4), and the combined organic phases were washed with saturated sodium chloride water (500 mL), dried over anhydrous sodium sulfate, and spun to dryness to obtain crude product. Beat with EA to obtain tert-butyl ((1r,4r)-4-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazole-2) -(yl)cyclohexyl)carbamate (7.00g).
- Step 1 Synthesis of tert-butyl 4-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carboxylate
- Step 2 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione
- Step 3 tert-Butyl 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1 -Synthesis of acetate
- Step 4 Synthesis of 2-(4-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetic acid
- Step 1 Synthesis of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate
- reaction solution was filtered through Celite, the filter cake was rinsed with ethyl acetate (100 mL), and the filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate. (9.20g).
- Step 2 Synthesis of 3-((6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-3-yl)amino)propionic acid
- Step 3 Synthesis of 1-(6-(4-acetylpiperazin-1-yl)pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 1 Synthesis of tert-butyl (1-(5-bromo-1,3,4-thiadiazol-2-yl)piperidin-4-yl)carbamate
- Step 4 tert-Butyl(1-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)piperidin-4-yl )Synthesis of urethane
- Step 2 Synthesis of 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidine-4-carboxylic acid
- Step 2 tert-Butyl 1-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)prop-2-yne-1 Synthesis of -yl)piperidine-4-carboxylate
- 1-Boc-4-piperidinecarboxylic acid (0.69g, 3.0mmol) and N,N-dimethylformamide (10mL) were added to a 50mL reaction bottle.
- 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.48g, 3.9mmol)
- N,N-di Isopropylethylamine (1.16g, 9.0mmol).
- 6-chloro-4-(methylamino)nicotinic acid hydrazide (0.60g, 3.0mmol) was added.
- the reaction system was raised to room temperature and reacted for 3 hours.
- Step 3 tert-Butyl 4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino)pyridin-3-yl Synthesis of )-1,3,4-thiadiazol-2-yl)piperidine-1-carboxylate
- ESI-MS(m/z):517.11[M+H] + .
- Step 3 Synthesis of 1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-carbaldehyde
- Step 4 tert-Butyl 1-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl )Methyl)piperidine-4-carboxylate synthesis
- Step 5 1-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl )Synthesis of piperidine-4-carboxylic acid
- Step 1 Synthesis of tert-butyl 2-(5-bromo-1,3,4-thiadiazol-2-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate
- Step 1 tert-Butyl((1r,4r)-4-(5-(6-(4-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamine) Synthesis of (yl)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)carbamate
- Step 2 1-(5-(5-((1r,4r)-4-aminocyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine-2 Synthesis of -yl)-1H-pyrrolo[2,3-b]pyridine-4-nitrile
- Step 1 tert-Butyl(S)-10-bromo-8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -3(4H)-carboxylic acid ester
- Step 2 tert-Butyl(S)-10-methyl-8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxane Synthesis of oxazine-3(4H)-carboxylate
- Step 3 tert-Butyl(S)-8-amino-10-methyl-1,2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -3(4H)-carboxylic acid ester
- Step 4 (S)-3-((3-(tert-butoxycarbonyl)-10-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2 -Synthesis of [1,4]oxazin-8-yl)amino)propionic acid
- Step 5 (S)-1-(3-acetyl-10-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1 ,Synthesis of 4]oxazin-8-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 6 (S)-1-(10-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -8-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 7 tert-Butyl(S)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-10-methyl-1,2,4a,5-tetrahydro Synthesis of benzo[b]pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetate
- Step 8 (S)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-10-methyl-1,2,4a,5-tetrahydrobenzo[ Synthesis of b]pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetic acid
- Step 1 Synthesis of tert-butyl (S)-4-(2-fluoro-4-nitrophenyl)-3-(hydroxymethyl)piperazine-1-carboxylate
- Step 2 tert-Butyl(S)-8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine-3(4H )-Synthesis of carboxylic acid esters
- Step 3 tert-Butyl(S)-8-amino-1,2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine-3(4H) -Synthesis of carboxylic acid esters
- Step 4 (S)-3-((3-(tert-butoxycarbonyl)-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][ Synthesis of 1,4]oxazin-8-yl)amino)propionic acid
- Step 5 (S)-1-(3-acetyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -8-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 6 (S)-1-(1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1,4]oxazin-8-yl) Synthesis of dihydropyrimidine-2,4(1H,3H)-dione
- Step 7 tert-Butyl(S)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1,2,4a,5-tetrahydrobenzo[b] Synthesis of pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetate
- Step 8 (S)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1,2,4a,5-tetrahydrobenzo[b]pyrazine[ Synthesis of 1,2-d][1,4]oxazin-3(4H)-yl)acetic acid
- step 2 to step 4 The operations from step 2 to step 4 are the same as steps 2 to step 4 in Intermediate Preparation Example 2 to obtain 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindoline-5-carbonyl)piperazin-1-yl)acetic acid (0.68 g).
- Step 1 Synthesis of di-tert-butyl 2-(4-(methoxycarbonyl)-3-methylphenyl)malonate
- Step 3 Synthesis of methyl 4-(2-(benzyloxy)-2-oxyethyl)-2-methyl benzoate
- Step 4 Synthesis of methyl 4-(2-(benzyloxy)-2-oxyethyl)-2-(bromomethyl)benzoate
- Step 5 Synthesis of benzyl 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetate
- Step 6 Synthesis of 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetic acid:
- Step 3 tert-Butyl 3-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino)pyridin-3-yl) Synthesis of -1,3,4-thiadiazol-2-yl)pyrrolidine-1-carboxylate
- the reaction solution was lowered to room temperature, poured into water (100 mL), and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over sodium sulfate, filtered, and concentrated to dryness under reduced pressure.
- Step 4 1-(4-(methylamino)-5-(5-(pyrrolidin-3-yl)-1,3,4-thiadiazol-2-yl)pyridin-2-yl)-1H- Synthesis of pyrrolo[2,3-b]pyridine-5-nitrile
- reaction solution was directly concentrated under reduced pressure to obtain crude product -(4-(methylamino)-5-(5-(pyrrolidin-3-yl)-1,3,4-thiadiazol-2-yl)pyridine-2- methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (0.80 g).
- Step 1 Synthesis of tert-butyl 3-(2-(6-chloro-4-(methylamino)nicotinoyl)hydrazinecarbonyl)azetidine-1-carboxylate
- Step 2 tert-Butyl 3-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)azetidine-1 -Synthesis of carboxylic acid esters
- Step 1 Synthesis of 6-chloro-4-((methyl-d 3 )amino)nicotinic acid methyl ester
- Step 2 Synthesis of 6-chloro-4-((methyl-d 3 )amino)nicotinic acid hydrazide
- N,N-dimethylformamide 100 mL
- 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate 11.93g, 31.38mmol
- N,N-diisopropylethylamine 11.06g, 85.59mmol
- Step 5 Methyl(1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-((methyl- d 3 ) Synthesis of amino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexane-1-carboxylate
- the reaction system was heated to 130°C under nitrogen protection for microwave reaction for 1.5 h.
- LCMS confirmed the end of the reaction.
- the reaction solution was filtered through diatomaceous earth. The filter cake was washed with ethyl acetate (100mL). The organic phase was collected and poured into water (200mL). The organic phase was separated. The water phase was continued to be washed with ethyl acetate (50mL). ⁇ 4) Extraction, combine the organic phases, wash twice with saturated sodium chloride aqueous solution (100 mL), dry, and concentrate to dryness under reduced pressure.
- Step 6 1-(5-(5-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-1,3,4-thiadiazol-2-yl)-4-((methyl -d 3 ) Synthesis of amino)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
- Step 7 1-(5-(5-((1r,4r)-4-formylcyclohexyl)-1,3,4-thiadiazol-2-yl)-4-((methyl-d3) Synthesis of amino)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
- Step 1 Synthesis of 1-(5-nitropyrimidin-2-yl)piperidine-4-carboxylic acid tert-butyl ester
- Step 2 Synthesis of tert-butyl 1-(5-aminopyrimidin-2-yl)piperidine-4-carboxylate
- Step 3 Synthesis of 3-((2-(4-(tert-butoxycarbonyl)piperidin-1-yl)pyrimidin-5-yl)amino)propionic acid
- Step 4 Synthesis of tert-butyl 1-(5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyrimidin-2-yl)piperidine-4-carboxylate
- Step 5 Synthesis of 1-(5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid
- Step 2 Synthesis of: (1r,4r)-4-((tert-butoxycarbonyl)(methyl-d 3 )amino)cyclohexane-1-carboxylic acid methyl ester
- Step 1 Synthesis of tert-butyl 4-(3-bromo-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
- Tetrahydrofuran 75 mL was added to 2-bromo-4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (5.00 g, 12.98 mmol) under nitrogen. After the reaction solution is cooled to -78°C, methyllithium (1.6M) (8.1mL, 12.98mmol) is slowly added dropwise. After the dropwise addition is completed, stir at -78°C for 30 minutes, and then n-butyllithium (2.5M) is added dropwise. (6.2 ml, 15.50 mmol) and continued stirring for 30 minutes.
- N,N-dimethylformamide (2.85g, 38.94mmol) was added dropwise at -78°C, and the reaction was stirred at -78°C for 1 hour.
- the reaction solution was slowly raised to room temperature, and stirring was continued for 1 hour.
- LCMS detects that the reaction is complete. Slowly pour the reaction solution into saturated ammonium chloride solution (30mL) to quench, adjust the pH of the reaction solution to 4-5 with 2N dilute hydrochloric acid, and then extract with ethyl acetate (100mL x 3).
- the organic phase is added with water (100mL) and Wash once with brine (100 mL), dry the organic phase over anhydrous sodium sulfate and concentrate to dryness under reduced pressure to obtain crude 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-formylbenzoic acid. .
- Step 4 Synthesis of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(((2,6-dioxopiperidin-3-yl)amino)methyl)benzoic acid
- Step 5 Synthesis of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate
- Step 2 Synthesis of methyl 2-(bromoethyl)-4,5-difluoromethyl benzoate
- Step 2 tert-Butyl 4-(3-methyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H- Synthesis of benzo[d]imidazol-4-yl)piperazine-1-carboxylate
- Step 3 Synthesis of tert-butyl 4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperazine-1-carboxylate
- the filtrate is concentrated to dryness under reduced pressure.
- Step 5 (R)-3-((3-(tert-butoxycarbonyl)-7-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2 -Synthesis of [1,4]oxazin-9-yl)amino)propionic acid
- Step 6 (R)-1-(3-acetyl-7-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1 ,Synthesis of 4]oxazin-9-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 7 (R)-1-(7-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -9-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 8 tert-butyl(R)-2-(9-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-7-methyl-1,2,4a,5-tetrahydrobenzene Synthesis of pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetate
- Step 9 (R)-1-(7-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine Synthesis of -9-yl)dihydropyrimidine-2,4(1H,3H)-dione
- Step 2 Synthesis of tert-butyl 2-(hydroxymethyl)-7-azaspiro[3.5]nonane-7-carboxylate
- Example 1 N-((1r,4r)-4-(5-(6-(5-cyano-1H-indol-1-yl)-4-(methylamino)pyridin-3-yl)- 1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Synthesis of indolin-5-yl)piperazin-1-yl)acetamide (compound 1)
- reaction system was reacted at 105°C for 16 hours under nitrogen protection. After the reaction was detected by LCMS, the reaction solution was cooled to room temperature, then filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate. The filtrate was collected, and the solvent was concentrated under reduced pressure to dryness.
- Step 2 1-(5-(5-((1r,4r)-4-aminocyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine-2- Synthesis of -1H-indole-5-nitrile
- Step 3 N-((1r,4r)-4-(5-(6-(5-cyano-1H-indol-1-yl)-4-(methylamino)pyridin-3-yl)-1 ,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole Synthesis of Dolin-5-yl)piperazin-1-yl)acetamide
- Example 4 Referring to the preparation method of Example 4, only 5-cyanoindole in Example 4 was replaced by 7H-pyrrolo[2,3-d]pyrimidine to obtain 2-(4-(2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoindolin-5-yl)piperazin-1-yl)-N-((1r,3r)-3-(5-(4- (Methylamino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclobutyl) Acetamide (80 mg). ESI-MS(m/z):761.19[M+H] + .
- Example 7 N-((1r,4r)-4-(5-(6-(3-cyanopyrrolo[1,2-b]pyridazin-7-yl)-4-(methylamino)pyridine -3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1 ,Synthesis of 2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetamide (compound 7)
- Step 1 7-(5-(5-((1r,4r)-4-aminocyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine-2- Synthesis of pyrrolo[1,2-b]pyridazine-3-nitrile:
- Step 2 N-((1r,4r)-4-(5-(6-(3-cyanopyrrolo[1,2-b]pyridazin-7-yl)-4-(methylamino)pyridine- 3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(8-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1, Synthesis of 2,4a,5-tetrahydrobenzo[b]pyrazine[1,2-d][1,4]oxazine-3(4H)-yl)acetamide:
- Example 8 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-(4-(2,4-dioxotetrahydropyrimidine-1(2H)) Synthesis of -yl)phenyl)piperazin-1-yl)acetamide (compound 8)
- Example 10 N-((1r,4r)-4-(5-(6-(5-cyano-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl )-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-(2-(2,6-dioxopiperyl) Synthesis of (din-3-yl)-1,3-dioxoisoindolin)-5-yl)piperazin-1-yl)acetamide (compound 10)
- Example 12 1-(5-(5-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl))-1,3-dioxoisoindole Phin-5-yl)piperazin-1-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)-1,3,4-thiadiazol-2-yl)-4 Synthesis of -(methylamino)pyridin-2-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (compound 12)
- Example 13 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-(2-(2,6-dioxopiperidin-3-yl)- Synthesis of 6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetamide (compound 13)
- Example 14 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-6-(2-((2-(2,6-dioxopiperidin-3-yl) Synthesis of -1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-azaspiro[3.3]heptane-2-carboxamide (compound 14)
- Step 1 1-(5-(5-((1r,4r)-4-aminocyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine-2- Synthesis of 1H-pyrrolo[2,3-b]pyridine-5-nitrile
- Step 2 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) Pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-6-(2-((2-(2,6-dioxopiperidin-3-yl)- Synthesis of 1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-azaspiro[3.3]heptane-2-carboxamide
- Example 16 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3 -Synthesis of dioxoisoindolin-4-yl)piperidine-4-carboxamide (compound 16)
- Example 17 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3 -Synthesis of dioxoisoindolin-5-yl)piperidine-4-carboxamide (compound 17)
- Step 1 tert-Butyl 4-(4-(5-(6-(6-cyanopyrazolo[1,5-a]pyrimidin-3-yl)-4-(isopropylamine)pyridine-3- Synthesis of (yl)-1,3,4-thiadiazol-2-yl)piperazine-1-carbonyl)piperidine-1-carboxylate
- Step 2 3-(4-(isopropylamino)-5-(5-(4-(piperidin-4-carbonyl)piperazin-1-yl)-1,3,4-thiadiazole-2 Synthesis of -yl)pyridin-2-yl)pyrazole[1,5-a]pyrimidine-6-nitrile
- Step 3 3-(5-(5-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4- (yl)piperidin-4-carbonyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)-4-(isopropylamino)pyridin-2-ylpyrazolo[1 ,Synthesis of 5-a]pyrimidine-6-nitrile
- reaction solution was reacted at 90°C for 3 hours.
- LCMS monitors that the reaction is completed.
- the reaction solution is cooled to 0°C, H 2 O (15 mL) is added to quench the reaction, ethyl acetate is added to extract three times, and washed three times with water and saturated sodium chloride aqueous solution.
- the organic phase is added to anhydrous sodium sulfate.
- Step 1 3-(3-methyl-2-oxo-4-(3-(piperidin-4-yloxy)prop-1-yn-1-yl)-2,3-dihydro-1H -Synthesis of benzo[d]imidazol-1-yl)piperidine-2,6-dione
- Step 2 tert-Butyl 2-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro) Synthesis of -1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)acetate
- Step 3 2-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H- Synthesis of benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)acetic acid
- Step 4 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) Pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(4-((3-(1-(2,6-dioxopiperidine-3- yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidine-1 -Acetamide synthesis
- Example 20 1-(5-(5-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl))-6-fluoro-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)-1,3,4-thiadiazol-2-yl) Synthesis of -4-(methylamino)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile (compound 50)
- the 5-cyanoindole in step 1 of Example 1 is replaced with 5-cyano-7-azaindole, and the 2-(4-(2,6-dioxanol) in step 3 Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetic acid crude product was replaced with 2-(4-(2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carbonyl)piperazin-1-yl)acetic acid crude product to obtain N-((1r,4r)-4-(5 -(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazole -2-yl)cyclohexyl)-2-(2-(2,6-dioxopiperidin
- Example 22 N-((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(7-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-2-yl) Synthesis of Acetamide (Compound 52)
- the 5-cyanoindole in step 1 of Example 1 is replaced with 5-cyano-7-azaindole, and the 2-(4-(2,6-dioxanol) in step 3 Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetic acid crude product was replaced with 2-(7-(2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-2-yl)acetic acid crude product, N -((1r,4r)-4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino)pyridine-3- yl)-1,3,4-thiadiazol-2-yl)cyclohexyl)-2-(7-(2-
- Example 23 1-(5-(5-(1-(2-(4-(2,6-dioxopiperidin-3-yl))-1,3-dioxoisoindoline-5 -yl)piperazin-1-yl)acetyl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridin-2-yl)- Synthesis of 1H-pyrrolo[2,3-b]pyridine-5-nitrile (compound 53)
- Step 1 1-(4-(methylamino)-5-(5-(piperidin-4-yl)-1,3,4-thiadiazol-2-yl)pyridin-2-yl)-1H -Synthesis of pyrrolo[2,3-b]pyridine-5-nitrile
- Step 2 tert-Butyl 4-(2-(4-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino) Synthesis of )pyridin-3-yl)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)-2-oxoethyl)piperazine-1-carboxylate
- Step 3 1-(4-(methylamino)-5-(5-(1-(2-(piperazin-1-yl)acetyl)piperidin-4-yl)-1,3,4- Synthesis of thiadiazol-2-yl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile
- Step 4 1-(5-(5-(1-(2-(4-((1-(2,6-dioxopiperidin-3-yl))-2-oxo-1,2-di Hydrobenzo[cd]indol-6-yl)methyl)piperazin-1-yl)acetyl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)-4 Synthesis of -(methylamino)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile
- Example 26 1-(5-(5-((1r,4r)-4-(((1-(2-(2,6-dioxopiperidin-3-yl))-1,3-di Oxoisoindolin-5-yl)piperidin-4-yl)methyl)amino)cyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine Synthesis of -2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile (compound 61)
- Step 1 1-(5-(5-((1r,4r)-4-aminocyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine-2- Synthesis of 1H-pyrrolo[2,3-b]pyridine-5-nitrile
- Step 2 1-(5-(5-((1r,4r)-4-(((1-(2-(2,6-dioxopiperidin-3-yl))-1,3-dioxo Isoindolin-5-yl)piperidin-4-yl)methyl)amino)cyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine- Synthesis of 2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile
- Example 27 1-(5-(5-((1r,4r)-4-(((1-(2-(2,6-dioxopiperidin-3-yl))-6-fluoro-1 ,3-Dioxoisoindolin-5-yl)piperidin-4-yl)methyl)amino)cyclohexyl)-1,3,4-thiadiazol-2-yl)-4-(methyl Synthesis of amino)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile (compound 65)
- Example 28 1-(5-(5-(1-(2-(4-(2-(2,6-dioxopiperidin-3-yl))-1,3-dioxoisoindole Phin-5-yl)piperazin-1-yl)acetyl)azetidin-3-yl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridine- Synthesis of 2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile (compound 68)
- Step 1 Synthesis of 2-chloro-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
- the reaction solution was concentrated to dryness under reduced pressure, water (20mL) was added to the concentrate, and extracted with ethyl acetate (20mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure.
- Step 2 Synthesis of tert-butyl 4-(1-(5-bromo-1,3,4-thiadiazol-2-yl)piperidin-4-yl)piperazine-1-carboxylate
- the concentrate was purified by preparative thin layer plate (ethyl acetate) to obtain tert-butyl 4-(1-(5-(6-chloro-4-fluoropyridin-3-yl)-1,3,4-thiadiazole- 2-yl)piperidin-4-yl)piperazine-1-carboxylate (70.0 mg, 31.5%).
- Step 4 tert-Butyl 4-(1-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)piperidine-4 Synthesis of -yl)piperazine-1-carboxylate
- the reaction solution was poured into water (20 mL), extracted with ethyl acetate (10 mL x 2), the organic phase was dried over sodium sulfate, filtered, and concentrated to dryness under reduced pressure.
- the concentrate was purified using thin layer preparative plate (ethyl acetate) to give tert-butyl 4-(1-(5-(6-chloro-4-(methylamino)pyridin-3-yl)-1,3,4-thi Diazol-2-yl)piperidin-4-yl)piperazine-1-carboxylate (100.0 mg, 47.0%).
- Step 5 tert-Butyl 4-(1-(5-(6-(5-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)-4-(methylamino)pyridine-3) Synthesis of -1,3,4-thiadiazol-2-yl)piperidin-4-yl)piperazine-1-carboxylate
- reaction system was raised to 100°C and reacted under nitrogen protection for 16 hours. LCMS showed the reaction was complete. After the reaction solution cooled to room temperature, it was poured into water (30mL) and extracted with ethyl acetate (15mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure.
- Step 6 1-(4-(methylamino)-5-(5-(4-(piperazin-1-yl)piperidin-1-yl)-1,3,4-thiadiazol-2-yl) Synthesis of )pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-nitrile
- reaction solution was concentrated to dryness under reduced pressure to obtain 1-(4-(methylamino)-5-(5-(4-(piperazin-1-yl)piperidin-1-yl)-1,3,4-thi Diazol-2-yl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (80.0 mg, crude product) and used directly in the next reaction.
- Step 7 1-(5-(5-(4-(4-(2-(2,6-dioxopiperidin-3-yl))-1,3-dioxoisoindoline-5- Carbonyl)piperazin-1-yl)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-4-(methylamino)pyridin-2-yl)-1H-pyrrolo[ Synthesis of 2,3-b]pyridine-5-nitrile
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un composé hétérocyclique chimérique bifonctionnel de la kinase 4 associée au récepteur de l'interleukine-1 (IRAK4) représenté par la formule (I), son procédé de préparation, une composition pharmaceutique de celui-ci et une utilisation associée. Le composé recrute IRAK4 en ubiquitine ligases, favorisant ainsi l'ubiquitination d'IRAK4 et la dégradation d'IRAK4 par des protéasomes. Des résultats de recherche montrent que le composé a une activité de dégradation d'IRAK4 relativement bonne et peut ainsi être utilisé pour traiter des maladies médiées par IRAK4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202380008533.1A CN117157298A (zh) | 2022-03-31 | 2023-03-31 | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210334860 | 2022-03-31 | ||
CN202210334860.3 | 2022-03-31 | ||
CN202211214397 | 2022-09-28 | ||
CN202211214397.5 | 2022-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023186069A1 true WO2023186069A1 (fr) | 2023-10-05 |
Family
ID=88199432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/085387 WO2023186069A1 (fr) | 2022-03-31 | 2023-03-31 | Composé hétérocyclique chimérique bifonctionnel de la kinase 4 associée au récepteur de l'interleukine-1, son procédé de préparation, composition pharmaceutique de celui-ci et utilisation associée |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117157298A (fr) |
WO (1) | WO2023186069A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024015340A1 (fr) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Ligands de céréblon et leurs utilisations |
WO2024056005A1 (fr) * | 2022-09-14 | 2024-03-21 | 先声再明医药有限公司 | Composé polycyclique et utilisation correspondante |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112105385A (zh) * | 2017-12-26 | 2020-12-18 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
CN112566915A (zh) * | 2018-08-13 | 2021-03-26 | 吉利德科学公司 | 噻二唑irak4抑制剂 |
WO2021168197A1 (fr) * | 2020-02-19 | 2021-08-26 | Nurix Therapeutics, Inc. | Agents de dégradation bifonctionnels de kinases associées au récepteur de l'interleukine-1 et leur utilisation thérapeutique |
CN114437035A (zh) * | 2020-11-06 | 2022-05-06 | 海思科医药集团股份有限公司 | 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用 |
WO2023023255A1 (fr) * | 2021-08-18 | 2023-02-23 | Nurix Therapeutics, Inc. | Agents bifonctionnels de dégradation de kinases associées au récepteur de l'interleukine-1 et leur utilisation thérapeutique |
-
2023
- 2023-03-31 CN CN202380008533.1A patent/CN117157298A/zh active Pending
- 2023-03-31 WO PCT/CN2023/085387 patent/WO2023186069A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112105385A (zh) * | 2017-12-26 | 2020-12-18 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
CN112566915A (zh) * | 2018-08-13 | 2021-03-26 | 吉利德科学公司 | 噻二唑irak4抑制剂 |
WO2021168197A1 (fr) * | 2020-02-19 | 2021-08-26 | Nurix Therapeutics, Inc. | Agents de dégradation bifonctionnels de kinases associées au récepteur de l'interleukine-1 et leur utilisation thérapeutique |
CN114437035A (zh) * | 2020-11-06 | 2022-05-06 | 海思科医药集团股份有限公司 | 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用 |
WO2023023255A1 (fr) * | 2021-08-18 | 2023-02-23 | Nurix Therapeutics, Inc. | Agents bifonctionnels de dégradation de kinases associées au récepteur de l'interleukine-1 et leur utilisation thérapeutique |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024015340A1 (fr) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Ligands de céréblon et leurs utilisations |
WO2024056005A1 (fr) * | 2022-09-14 | 2024-03-21 | 先声再明医药有限公司 | Composé polycyclique et utilisation correspondante |
Also Published As
Publication number | Publication date |
---|---|
CN117157298A (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112437772B (zh) | Bcl-2抑制剂 | |
WO2021219072A1 (fr) | Préparation et procédé d'application d'un composé hétérocyclique en tant qu'inhibiteur de kras | |
ES2768996T3 (es) | Pirrolopirimidinas y pirazolopirimidinas utilizadas como inhibidores de la proteasa específica de ubiquitina 7 | |
AU2010320963B2 (en) | Novel heterocyclic acrylamides and their use as pharmaceuticals | |
KR102604942B1 (ko) | 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물 | |
WO2023186069A1 (fr) | Composé hétérocyclique chimérique bifonctionnel de la kinase 4 associée au récepteur de l'interleukine-1, son procédé de préparation, composition pharmaceutique de celui-ci et utilisation associée | |
EP1963320A1 (fr) | Composes inhibant les pyrrolopyridine kinases | |
AU2014307437A1 (en) | Novel fused pyrimidine compound or salt thereof | |
CN115594666B (zh) | 一种磷酸酶降解剂的合成和应用 | |
AU2014230111A1 (en) | Macrocyclic RIP2 kinase inhibitors | |
WO2019076336A1 (fr) | Dérivé tricyclique contenant du pyrazolyle, son procédé de préparation et son utilisation | |
TW202400581A (zh) | 驅動蛋白kif18a抑制劑及其應用 | |
JP2023538091A (ja) | Btk阻害剤としての複素環式化合物 | |
TW201833113A (zh) | 作為P13Kδ抑制劑之咪唑并[1,5-A]吡衍生物 | |
CA3092770A1 (fr) | Derives d'imidazolidine-2-one substitues en tant qu'inhibiteurs de prmt5 | |
CN114835687B (zh) | AhR抑制剂 | |
AU2021283916A1 (en) | Kinase inhibitors | |
TW202317561A (zh) | 作為治療劑的具有1h—吡唑并[4,3—c]吡啶—6—胺基的化合物 | |
JP7312171B2 (ja) | ピラゾロピリジノン化合物 | |
WO2022253309A1 (fr) | Composés hétérocycliques substitués et leur utilisation | |
WO2022198069A1 (fr) | Composés comprenant un ((3-nitrophényl)sulfonyl)acétamide en tant qu'inhibiteurs de bcl-2 | |
CA3080623C (fr) | Compose presentant une activite inhibitrice de kinase erk et son utilisation | |
WO2021018118A1 (fr) | Composés et procédés pour la dégradation ciblée de protéines de kinase 1 associés au récepteur de l'interleukine 1 | |
TW202128689A (zh) | 氮雜苯並咪唑化合物及醫藥 | |
KR20210108433A (ko) | 티에노피리디논 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23778434 Country of ref document: EP Kind code of ref document: A1 |